

Serial No. 09/818,943

Attorney Docket: 1064/48487

REMARKS

As an initial matter, the undersigned wishes to express his gratitude to Examiners Whiteman and Reynolds for their courtesies during an Office Interview conducted on April 28, 2003.

Applicants have amended the claims pursuant to the kind suggestions of the Examiners during the interview. The claim amendments are fully supported by the specification originally filed. For example, support for amendment to Claim 1 can be found at page 10, lines 9-11; and support for Claim 28 can be found at e.g. the paragraph bridging pages 16 and 17.

As amended, Claim 1 recites a method for producing a transgenic mouse which overexpresses a polypeptide having PDGF-C activity and develops hypertrophy or fibrosis in at least one of its organs. Applicants respectfully submit that in view of the claim amendment, the basis of the lack of enablement rejection, i.e., the transgenic mouse lacking "substantial and specific utility," no longer exists. Accordingly, applicants respectfully submit that the claims are now in condition for allowance.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. 05-1323 (Docket #1064/48487).

May 19, 2003

Respectfully submitted,



Kening Li, Ph.D.
Registration No. 44,872
J. D. Evans
Registration No. 26,269

CROWELL & MORING, LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
JDE:KL:tlm (029085.48487US)